L
Lisata Therapeutics, Inc. (LSTA)
NCM – Real Time Price. Currency in USD
3.26
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.26
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, CEO & Director |
| Dr. Kristen K. Buck M.D. | Executive VP of R&D and Chief Medical Officer |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
| Mr. Gregory S. Berkin | Chief Information & Data Protection Officer |
| Mr. James Nisco | Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer |
| Mr. John D. Menditto | Vice President of Investor Relations & Corporate Communications |
| Mr. Tariq Imam | Senior VP of Business Development & Operations and General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | SC14D9C | ef20072321_formsc14d9c.htm |
| 2026-05-04 | 8-K | ef20072320_form8k.htm |
| 2026-04-28 | 10-K/A | clbs-20251231.htm |
| 2026-04-15 | SC14D9C | ef20070657_sc14d9c.htm |
| 2026-04-15 | 8-K | ef20070652_form8k.htm |
| 2026-04-03 | 8-K | ef20069819_8k.htm |
| 2026-03-12 | 10-K | lsta-20251231.htm |
| 2026-03-09 | SC14D9C | ef20067380_sc14d9c.htm |
| 2026-03-09 | 8-K | clbs-20260306.htm |
| 2026-02-27 | SC14D9C | ef20066670_sc14d9c.htm |